Identification of compounds selectively killing multidrug-resistant cancer cells

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Multidrug resistance (MDR) in cancer poses a significant challenge to effective chemotherapy.
• Developing novel chemotherapeutic agents to overcome MDR is a critical area of research.

Purpose of the Study:

• To identify compounds with selective toxicity against multidrug-resistant cancer cells from the National Cancer Institute's DTP drug repository.
• To explore potential mechanisms of action and structure-activity relationships for MDR-selective compounds.

Main Methods:

• Screening of the National Cancer Institute's DTP drug repository for compounds exhibiting increased toxicity in MDR cancer cell lines compared to parental cell lines.
• Analysis of structural congeners to identify additional MDR-selective drugs, particularly those effective against P-glycoprotein (Pgp)-expressing cells.
• Data mining and experimental validation to establish structure-activity relationships and pharmacophore models.

Main Results:

• Identified 22 compounds with MDR-selective activity.
• Discovered 15 additional drugs effective against Pgp-expressing cells.
• Formulated structure-activity relationships and pharmacophore models for MDR-selective compounds.
• Evidence suggests a potential mechanism of action involving metal chelation.

Conclusions:

• The identified set of MDR-selective compounds demonstrates the potential of MDR-targeting therapy.
• This approach represents a robust new strategy for overcoming P-glycoprotein-mediated multidrug resistance in cancer.
• Further research into these compounds could lead to improved cancer treatment outcomes.